Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications.
Allergy
; 77(4): 1105-1113, 2022 04.
Article
em En
| MEDLINE
| ID: mdl-34478578
ABSTRACT
A significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long-acting ß2 adrenergic bronchodilators (LABA). The addition of long-acting antimuscarinic agents (LAMA) can improve the management of asthma in these patients. Recently, three novel triple therapy (ICS/LABA/LAMA) formulations in a single-inhaler device (SITT) have been investigated in patients with uncontrolled asthma despite ICS/LABA treatment. Here, we review systematically the evidence available to date in relation to SITT in patients with uncontrolled asthma despite ICS-LABA treatment and conclude that SITT is a safe and effective therapeutic alternative in these patients. We also discuss how to position this new therapeutic alternative in their practical clinical management as well as the opportunities and challenges that it may generate for patients, physicians, and payers.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Doença Pulmonar Obstrutiva Crônica
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Allergy
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Espanha